Janssen's Stelara secures NICE nod before looming competition
This article was originally published in Scrip
Executive Summary
Janssen has won NICE's recommendation for psoriatic arthritis drug Stelara (ustekinumab) in draft guidance, after the company offered a patient access scheme (PAS). With competition in the psoriasis market heating up, the recommendation is timely for Stelara, which NICE had previously turned down.